Kornimate/medical-research-clean huggingface dataset:
packhealth: asthma engagement tool

Conditions: Asthma

Summary: the purpose of this study is to test the impact of an innovative patient engagement solution on patient's quality of life and asthma-related outcomes, and evaluate the correlation between a patient reported outcome measure and clinical outcomes.

patient engagement is a critical part of improving patient care and outcomes. current patient engagement strategies only focus on the patient-physician interaction and have been shown to be ineffective. the need for a comprehensive approach to patient engagement is no different among patients with asthma as it is in any other chronic condition. patients with asthma must make complicated health decisions daily that impact their social and occupational activities, quality of life, and treatment adherence. obtaining, communicating, processing, and understanding non- biased health information are crucial in making appropriate and informed treatment decisions. pack health llc and duke will develop a patient engagement toolkit known as "packs" to help empower and engage patients. these disease-specific, evidence-based kits are scientifically designed to improve patient involvement in their own care. each pack draws on the science of change management and patient activation and contains three categories of materials

Eligibility criteria:
inclusion criteria: * patients with a physician diagnosis of asthma for at least the previous 12 months. * asthma that is not well controlled by naepp guidelines. * ability and willingness to provide informed consent exclusion criteria: * significant alcohol consumption of more than three alcoholic drinks per day or active substance abuse. * chronic disease (other than asthma) that in the opinion of the investigator would prevent participation in the trial or put the participant at risk by participation e.g. chronic diseases of the lung (other than asthma), heart, liver, kidney, endocrine or nervous system or immunodeficiency that are not well addressed or controlled. * a diagnosis of cancer with ongoing treatment. * any terminal illness or conditions that results in a life expectancy less than one year.
elimination of incretin hormones in patients with severe kidney failure

Conditions: Uremia

Summary: the prevalence of type 2 diabetes (t2d) is increasing rapidly worldwide. t2d is characterized by a severely impaired incretin effect. the incretin effect refers to the insulinotropic action of the nutrient-released incretin hormones glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic peptide (gip). the incretin effect is defined as the difference in insulin secretory responses between oral and isoglycaemic intravenous glucose challenges (ogtt and iigi, respectively) and in healthy individuals it accounts for as much as 70% of the insulin response following oral glucose, whereas patients with t2d exhibit an incretin effect in the range of 0 to 30%. patients with t2d and non-diabetic patients with severe kidney failure share several pathophysiological characteristics, including decreased insulin sensitivity, fasting hyperinsulinaemia and impaired beta-cell function. the reason for these findings remains to be fully elucidated. an ongoing study in our research group is investigating the incretin effect and the incretin hormone secretory responses following ogtt, iigi and meal ingestion, respectively. in continuation of this study, essential knowledge of metabolism of incretin hormones in an uremic milieu will be obtained in the present study prior to evaluation of the use of incretin-based agents in patients with impaired kidney function. in this second study we evaluate the elimination and biodegradation of glp-1 and gip. the biological active incretin hormones are rapidly degraded by the ubiquitous enzyme dipeptidyl peptidase-4 (dpp-4), generating inactive metabolites. the active hormones are however also eliminated by renal clearance, although the importance of this remains questionable. it is likely that the degradation and elimination of the active hormones will be significantly affected in patients with severe kidney impairment. we hypothesize that elimination and biodegradation of the two incretin hormones, both in it´s active and inactive forms, will be affected in non-diabetic patients with severe kidney failure.


Eligibility criteria:
1) inclusion criteria: * male or female; aged 18-90 years * ckd stage 5 in chronic maintenance dialysis treatment * bmi: 18,5-28 kg/m2 * normal fasting plasma glucose (\<6,1 mm) * normal or impaired glucose tolerance (pg120 min \<11,1 mm following ogtt) inclusion criteria: * male or female; aged 18-90 years * healthy including normal kidney function * bmi: 18,5-28 kg/m2 * normal fasting plasma glucose (\<6,1 mm) * normal or impaired glucose tolerance (pg120 min \<11,1 mm following ogtt) 1+2) exclusion criteria: * diabetes mellitus * chronic pancreatitis / previous acute pancreatitis * treatment with oral glucocorticoids, calcineurin inhibitors, thiazides, dipeptidyl peptidase 4 (dpp4) inhibitors or other drugs, which could interfere with glucose or lipid metabolism * inflammatory bowel disease * malignant disease * bowel resection * severe anemia (hemoglobin \<6.5 mmol/l)

Keywords: incretin hormones glp-1 gip uremia dialysis
whole blood collection from individuals in the convalescent phase of sars-cov-2 infection

Conditions: COVID; Sars-CoV2

Summary: the study was not opened.


Eligibility criteria:
inclusion criteria: patients who have previously been diagnosed with covid-19 but are now asymptomatic \>14 days and a matched number of healthy controls: 1. consent: subject able to provide voluntary written consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care. 2. sars-cov-2 testing status: 1. experimental population: subject has had positive sars-cov-2 verified by clinical laboratory or 2. control population: subject without testing or negative sars-cov-2 testing 3. complete resolution and current absence of clinical symptoms symptoms defined as: fever, dry cough, fatigue, difficulty breathing, sore throat, diarrhea, rhinorrhea (runny nose), or new aches/pains. 4. age: greater or equal to 18 years of age. a. subject must be able to provide voluntary written consent exclusion criteria: 1. ongoing symptoms of covid19 due to sars-cov-2 infection a. symptoms defined as: fever, dry cough, fatigue, difficulty breathing, sore throat, diarrhea, rhinorrhea (runny nose), or new aches/pains. 2. ongoing symptoms not due or not known to be due to sars-cov-2 infection a. symptoms defined as: fever, dry cough, fatigue, difficulty breathing, sore throat, diarrhea, rhinorrhea (runny nose), or new aches/pains. 3. patients receiving ongoing medical symptomatic treatment or prophylaxis treatment related to covid-19 due to sars-cov-2
natural cycle versus endometrial preparation for healthy blastocyst transfer

Conditions: Infertility

Summary: this study evaluates the difference in pregnancy rate transferring a healthy blastocyst in natural or artificial cycle.

the aim of the study was to verify the implantation capacity and ongoing pregnancy rate of vitrified warmed euploid blastocyst in natural cycle versus endometrial artificial cycle with gonadotropin-releasing hormone (gnrh-agonist) pituitary suppression.

Eligibility criteria:
inclusion criteria: * frozen-thawed healthy blastocyst exclusion criteria: * post thawed not survival healthy blastocyst
machine learning versus traditional scores in predicting erythrocyte need

Conditions: Erythrocyte Transfusion; Machine Learning

Summary: in this study, we compared perioperative bleeding prediction scores with our machine learning-based prediction system in predicting the need for erythrocyte suspension during cardiovascular surgery.

the success of ml algorithms in predicting perioperative blood product use in cabg remains an under-tested topic. unnecessary preparation of blood products or not being able to supply them when necessary is critical for both patient safety and the effective use of hospital resources \[8\]. bleeding amounts and blood product use strategies can vary with institute protocols. scoring systems that determine the general framework may not perform well due to local factors. ml algorithms can be created locally according to previous patient data of each clinic and can improve themselves with learning mechanisms, suggesting significant potential in this field. in the current study, a new estimation system created with the ml algorithm was compared with the known estimation systems. comparing the ml algorithm with 6 different classical scoring systems is important in terms of demonstrating the potential of this technology. the aim of this study is to investigate whether the model created with ml in predicting perioperative blood product consumption in cardiovascular surgeries is superior to predictive scoring systems that have proven themselves in the literature. secondary aim is to compare the predictive value of using more than one scoring system in combination.

Eligibility criteria:
inclusion criteria: * data from patients who underwent isolated cabg surgeries in the cardiac and vascular surgery operating rooms between 01.01.2023 and 01.01.2024 were evaluated. exclusion criteria: * missing data * emergency surgery * i̇ntraoperative mortality

Keywords: machine learning cardiovascular surgery perioperative bleeding erythrocyte transfusion predictive modeling
abdominal binder and steps trial

Conditions: Post-operative Milestones

Summary: large lower abdominal incisions are still used in many types of common gynecologic surgeries. patients may experience pain and restrictions to ambulation because of this, which can make healing after surgery harder and more complicated. abdominal binders, through their added abdominal support, may provide a low cost intervention to help people heal. the study team aims to investigate the effects of abdominal binders on walking in the post- gynecologic surgery period.

laparotomy is a commonly utilized modality for abdominal entry in benign gynecologic surgery despite preference for minimally invasive techniques when surgically feasible. as with other major abdominal surgeries, patients may experience pain and restrictions to ambulation related to the abdominal incision that complicate the postoperative period. abdominal binders, through their added abdominal support, may provide a low cost, noninvasive intervention to enhance this vital recovery period. though the use of abdominal binders have been studied extensively in the postcesarean section patient, no report to date exists assessing the effects on abdominal binders in the postoperative course of benign gynecologic surgeries. the study team aims to investigate the effects of abdominal binders on ambulation in the postoperative period after laparotomy for benign gynecologic surgery. the primary outcome is quantitative ambulation via electronic step counter. secondary outcomes include time to ambulation, quantitative narcotic utilization, visual analogue pain scale, subjective overall wellbeing. with 85% power the study team attempts to calculate a 1200 step difference in means between abdominal binder and control groups using 67 patients per study arm.

Eligibility criteria:
inclusion criteria: * english-speaking * female * patients undergoing benign hysterectomy or myomectomy via low-transverse laparotomy. exclusion criteria: * asa classification of three or higher * malignancy * non-english speaking

Keywords: post-operative ambulation post-operative pain abdominal binder step counter
va-005 clinical outcomes of vigiv treatment of smallpox vaccination complications or vaccinia infection

Conditions: Complication of Smallpox Vaccination

Summary: this is a post-marketing study to verify the clinical benefits of vigiv \[cnj-016, vaccinia immune globulin intravenous (human), sterile solution\] in the resolution of complications resulting from smallpox vaccination in eligible patients treated with vigiv.

this is an open-label phase 4 study designed to collect additional data to assess the safety and efficacy of vigiv \[cnj-016, vaccinia immune globulin intravenous (human), sterile solution\] in the first 100 consented patients treated with vigiv.

Eligibility criteria:
inclusion criteria: subjects treated with vigiv deployed from the us strategic national stockpile for any of the following conditions: * eczema vaccinatum. * progressive vaccinia. * severe generalized vaccinia. * vaccinia infections in individuals who have skin conditions such as burns, impetigo, varicella-zoster, or poison ivy, or in individuals who have eczematous skin lesions because of either the activity or extensiveness of such lesions. * aberrant infections induced by vaccinia virus that include its accidental implantation in eyes (except in cases of isolated keratitis), mouth, or other areas where vaccinia infection would constitute a special hazard. * informed consent voluntarily signed by subject, legal guardian or representative to participate in the study. for minors, the informed consent form must be signed by a legally acceptable representative and when appropriate, informed consent/assent must also be obtained from the minor. exclusion criteria: none.

Keywords: smallpox vaccination complications
factors that impact the relationship between pulmonary status and susceptibility to electronic cigarette use

Conditions: Electronic Cigarette Use; Pulmonary Disease

Summary: the purpose of the study is to explores various psycho-social, physiological, cognitive, behavioral, and environmental factors that may affect the association between pulmonary status and susceptibility to electronic cigarette use

in this study self-report questionnaires will be distributed and it should take between 20-25 minutes. participants will be be asked questions related to smoking history, e-cigarette use, psychosocial factors, behavioral factors, environmental factors, and cognitive factors. there is also an option of taking a web-based survey, qualtrics® (qualtrics, provo, ut), if they do not have enough time to complete the surveys at this time. the online version of the questionnaires will be sent to the one week from now. there is also a follow-up 5 minutes call with 6 months after today to follow-up with any change regarding to e-cigarette use.

Eligibility criteria:
inclusion criteria: pulmonary are 18 years of age or older. attend outpatient pulmonary clinic at uab diagnosed with a pulmonary disease speak english as primary language are medically stable and without psychiatric disorders. signed informed consent healthy are 18 years of age or older. free from any pulmonary disease report good to excellent general health speak english as primary language signed informed consent exclusion criteria: pulmonary are younger than 18 years of age do not attend the outpatient pulmonary clinic at uab (pulmonary group) report current e-cigarette use are non-english speakers have unstable medical or psychiatric disorders as determined by the assigned medical doctor (pulmonary group) refuse to sign the informed consent healthy are younger than 18 years of age report any pulmonary diseases (control group) report fair to poor general health (control group) report current e-cigarette use are non-english speakers refuse to sign the informed consent

Keywords: susceptibility to electronic cigarette use
two fluid strategies for prevention of post-dural puncture headache

Conditions: Post-Dural Puncture Headache

Summary: postdural puncture headache (pdph) is a common complication after cesarean delivery (cd). the role of peri-operative fluid therapy in prophylaxis against pdph is unclear. the aim of this work is to compare restrictive versus liberal fluid therapy in prophylaxis against pdph after cd

in this study, the investigators will compare restrictive fluid therapy and liberal fluid therapy in prophylaxis against postdural puncture headache. the restrictive group will not receive preoperative fluid loading, and will receive intraoperative crystalloids at rate of 10 ml/kg/hour followed by postoperative crystalloids at rate of 2 ml/kg/hour for hours. the liberal group will receive preoperative fluid loading of 5 ml/kg, and will receive intraoperative crystalloids at rate of 10 ml/kg/hour, followed by postoperative crystalloids at rate of 6 ml/kg/hour. both groups will be compared regarding demographic data, total peri-operative fluids, incidence of postdural puncture headache, nausea, vomiting, and intraoperative hemodynamics (heart rate and systolic blood pressure) in addition to neonatal outcomes.

Eligibility criteria:
inclusion criteria: * full term * pregnant female * scheduled to elective cesarean delivery exclusion criteria: * history of migraine headache * hypertensive disorders of pregnancy * cardiac morbidities, * baseline systolic blood pressure \< 100 mmhg * contraindication of regional anesthesia. * patients with more than one single attempt for spinal block
expression and the clinical significance of neutrophil pd-l1 during sepsis

Conditions: Sepsis; Immunosuppression

Summary: immunosuppression is the leading cause of death in septic patients. neutrophils are classical components of innate immunology, but recent studies showed that neutrophils might display antigen presenting function and inhibit lymphocyte proliferation by expressing programmed cell death 1 ligand 1 (pd-l1). whether neutrophils express pd-l1 and its role in immunosuppression during sepsis remain unclear.


Eligibility criteria:
inclusion criteria: * patients with severe sepsis * patients with sepsis after pcnl for infectious kidney stone * patients with pancreatic cancer * healthy volunteers exclusion criteria: * patients with immunodeficient diseases * patients who accept glucocorticoid or immunosuppressant * patients with an age older than 18 years * patients providing the informed consent

Keywords: sepsis immunosuppression pd-l1
mechanisms of inflammatory liver injury

Conditions: Liver Diseases

Summary: white blood cells can cause liver damage if they inappropriately accumulate in the liver in large numbers. such an event can occur if an individual's blood is exposed to endotoxin, a substance released from the cell walls of many species of bacteria. the purpose of this study is to isolate neutrophils, an important white blood cell, from the blood of normal volunteers, and put them in tissue culture with isolated liver cells. the experiments will determine how endotoxin can increase the ability of neutrophils to damage liver cells. all studies supported by this grant will be done with isolated cells in tissue culture. this experimental model will reveal possible mechanisms that can in the future be evaluated in human diseases such as bacterial sepsis.

neutrophils will be isolated from normal human volunteers and placed in cell culture with isolated hepatocytes or c3a cells (hepatoblastoma cell line that exhibit many characteristics of normal hepatocytes). these experiments will evaluate the mechanisms by which neutrophil adhere to the surface of hepatocytes, and the mechanisms by which the attached neutrophils can damage or kill the hepatocytes. mechanisms of adhesion will involve understanding of the chemokines released by the hepatocytes that stimulate neutrophil adhesiveness, the cytokines that activate hepatocytes to express chemokines and adhesion molecules, the adhesion receptors on the neutrophil surface that are able to recognize the adhesion molecules on the hepatocyte surface, and the ability of adhesion to enhance and focus cytotoxic chemicals coming from the stimulated neutrophils. in addition, the role endotoxin can play in these sequence of events is being studies, and the specific cytotoxic mechanisms released by the neutrophils are under study. as noted in the brief summary, this grant only supports use of human cells in vitro (i.e., all experiments will be done in tissue culture). the purpose of working with this experimental model is to define what mechanisms should in future experiments be evaluated in patients with endotoxin induced disease.

Eligibility criteria:
only blood from normal subjects will be used in the in vitro experiments.

Keywords: liver inflammation endotoxin neutrophils hepatocytes
benefits of pulmonary rehabilitation to patients post liver transplant

Conditions: Liver Transplant Surgery

Summary: the goal of this clinical trial was to access the benefits of a 12-week home-based pulmonary rehabilitation regimen on pulmonary function recovery in post-liver transplant patients. the main questions it aims to answer are: does pulmonary rehabilitation facilitate pulmonary muscle strength recovery? does the intervention improve pulmonary function and reduce dyspnea sensation? participants performed: inspiratory muscle training twice a day for 12 weeks after discharged from the hospital upper limb resistive training lower limb exercise

patients undergoing liver transplantation often face significant challenges related to pulmonary rehabilitation. although postoperative rehabilitation has been extensively studied, the specific role of pulmonary rehabilitation programs has received limited attention. this study aims to evaluate the efficacy of a home-based pulmonary rehabilitation program in improving respiratory function recovery among post-liver transplant patients. the training group participated in a 12-week pulmonary rehabilitation program post-discharge, emphasizing respiratory muscle and exercise training, while the control group received standard care, which included traditional rehabilitation.

Eligibility criteria:
inclusion criteria: * age 20 years or older * scheduled to undergo living donor liver transplantation * stable vital signs * normal cognitive function * able to perform activities independently using their own strength and coordination * willing and able to participate in 12 weeks of rehabilitation training exclusion criteria: * severe physical illness during the operation * acute bleeding * unstable vital signs * hepatic encephalopathy, or neurological conditions such as stroke, parkinson\&#39;s disease, or cognitive dysfunction * limited mobility (e.g., unable to stand, lift upper limbs, or bedridden) * inability to comply with 12 weeks of pulmonary rehabilitation post-discharge * unstable vital signs * hepatoencephalopathy, such as cardiovascular accident, parkinson disease, cognitive dysfunction * those with limited mobility (unable to stand, unable to lift upper limbs, or bedridden) * those who are unable to cooperate with the 12 weeks of pulmonary rehabilitation exercises after discharge.

Keywords: liver transplant pulmonary rehabilitation inspiratory muscle training inspiratory muscle strength dyspnea